Table 1 Concentrations of treatments added

VEGF165

Positive control

n/a

20 ng/ml

Peprotech (London, UK)

Tumour necrosis factor-alpha (TNF-α)

Positive control

n/a

160 pg/ml

Enzo Life sciences, (Exeter, UK)

CathL

Treatment

n/a

50 ng/ml

Sigma-Aldrich (Poole, UK)

Gal1

Treatment

n/a

1, 5, 10, 25, 50, 125 ng/ml

Sigma-Aldrich (Poole, UK)

Sulfasalazine

NFκB inhibitor

24 h

100 µmol/l

Stratech (Suffolk, UK)

U0126

MEK/ERK1/2 inhibitor

20–30 min

10 µmol/l

Stratech (Suffolk, UK)

PD98059

MEK/ERK1/2 inhibitor

20–30 min

25 µmol/l

Stratech (Suffolk, UK)

LY294002

PI3K inhibitor

1–2 h

25 µmol/l

Stratech (Suffolk, UK)

MK2206

AKT inhibitor

1–2 h

5 µmol/l

Stratech (Suffolk, UK)